CD163 and breast cancer: To objectively determine the relationship between clinical outcome and proximity of CD163+ M2-like TAMs to breast cancer cells, three-color immunofluorescence (IF) images of breast cancer tissue microarrays were immunolabeled for cytokeratin (CK) and CD163 and counterstained with DAPI.